| 发明名称 |
INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS |
| 摘要 |
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism. |
| 申请公布号 |
US2014322266(A1) |
申请公布日期 |
2014.10.30 |
| 申请号 |
US201414216887 |
申请日期 |
2014.03.17 |
| 申请人 |
ActoGeniX N.V. |
发明人 |
Rottiers Pieter;Snoeck Veerle |
| 分类号 |
A61K39/00;A61K35/74 |
主分类号 |
A61K39/00 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A medicament, nutraceutical or medical food for treating and/or alleviating type I diabetes or for inducing immune tolerance to type I diabetes comprising at least a beta cell autoantigen in type I diabetes in combination with an IL-10 secreting Lactococcus lactis. |
| 地址 |
Zwijnaarde BE |
